7.86% 0.0204

Calidi Biotherapeutics Inc (CLDI)

Überblick Nachrichten Preisverlauf Forum Prognose

Schlusskurs vom Vortag:

24-Stunden-Volumen:

Relative Volume:

Marktkapitalisierung:

Nettoeinkommen (Verlust:

Netto-Cashflow:

1W Leistung:

1M Leistung:

6M Leistung:

1J Leistung:

1-Tages-Spanne:

1-Wochen-Bereich:

52-Wochen-Spanne:

Calidi Biotherapeutics Inc Stock (CLDI) Company Profile

Calidi Biotherapeutics Inc

Healthcare (1171)

Biotechnology (661)

(858) 794-9600

4475 Executive Drive, Suite 200, San Diego

Nächster Verdiensttermin

Neueste SEC-Einreichungen

CLDI's Discussions on Twitter

Vergleichen Sie CLDI mit anderen Aktien

Aktien	Preis	Marktkapitalisierung	Umsatz	Nettogewinn	Free Cashflow	ENV
CLDI Calidi Biotherapeutics Inc	0.249	10.93M	0	-23.36M	0	-0.7368
VRTX Vertex Pharmaceuticals Inc	444.17	115.95B	11.10B	-988.90M	-1.26B	-3.92
REGN Regeneron Pharmaceuticals Inc	527.50	56.52B	14.09B	4.50B	2.96B	39.28
ALNY Alnylam Pharmaceuticals Inc	317.32	39.44B	2.35B	-269.70M	-75.39M	-2.09
ARGX Argen X Se Adr	562.85	35.14B	2.58B	1.06B	-1.28B	16.33
ONC Beone Medicines Ltd Adr	242.77	28.51B	3.81B	-644.79M	-669.77M	-6.24

Calidi Biotherapeutics Inc Stock (CLDI) Upgrades & Downgrades

Datum	Aktion	Analytiker	Ratingänderung
2023-11-22	Eingeleitet	H.C. Wainwright	Buy
2023-10-09	Eingeleitet	Robert W. Baird	Outperform

Calidi Biotherapeutics Inc Aktie (CLDI) Neueste Nachrichten

Finanzdaten der Calidi Biotherapeutics Inc-Aktie (CLDI)

Calidi Biotherapeutics Inc (CLDI)

Calidi Biotherapeutics Inc Stock (CLDI) Company Profile

Vergleichen Sie CLDI mit anderen Aktien

Calidi Biotherapeutics Inc Stock (CLDI) Upgrades & Downgrades

Calidi Biotherapeutics Inc Aktie (CLDI) Neueste Nachrichten

Millennium Management LLC Increases Stake in Calidi Biotherapeutics, Inc. (NYSE:CLDI) - Defense World

Calidi Biotherapeutics Appoints Biotech Veteran Eric Poma, PhD, as CEO to Lead Next Growth Phase - citybuzz -

Jane Street Group LLC Takes Position in Calidi Biotherapeutics, Inc. (NYSE:CLDI) - Defense World

Calidi Biotherapeutics Unveils Promising Data on CLD-401 at ASCO 2025 - citybuzz -

Calidi Biotherapeutics Presents systemic oncolytic platform - GlobeNewswire

Calidi Biotherapeutics (CLDI) Showcases Innovative CLD-401 Thera - GuruFocus

Revolutionary Cancer Treatment Breakthrough: Calidi's New Systemic Delivery Platform Wows ASCO Conference - Stock Titan

Calidi Biotherapeutics Announces Closing of $4.25 Million Public Offering of Common Stock - The Globe and Mail

Calidi Biotherapeutics (NYSE:CLDI) Shares Down 5.3% – Time to Sell? - Defense World

Calidi Biotherapeutics, Inc. (CLDI) Forms 'Hammer Chart Pattern': Time for Bottom Fishing? - Yahoo Finance

Calidi Biotherapeutics Reports First Quarter 2025 Financial Results And Recent Operational Highlights - marketscreener.com

Calidi Biotherapeutics Reports First Quarter 2025 Financial Results and Recent Operational Highlights - GlobeNewswire

Calidi Biotherapeutics Secures FDA Green Light for Cancer Trial as New CEO Reveals Q1 Financials - Stock Titan

Candel Therapeutics (NASDAQ:CADL) vs. Calidi Biotherapeutics (NYSE:CLDI) Critical Review - Defense World

Geode Capital Management LLC Buys 120,406 Shares of Calidi Biotherapeutics, Inc. (NYSE:CLDI) - Defense World

CLDICalidi Biotherapeutics Inc Latest Stock News & Market Updates - Stock Titan

Join Calidi Biotherapeutics’ Exclusive Live Investor Webinar and Q&A Session on February 5 - The Globe and Mail

Calidi Biotherapeutics (NYSE:CLDI) Stock Price Down 0.3% – Time to Sell? - Defense World

Investor’s Delight: Calidi Biotherapeutics Inc (CLDI) Closes Weak at 0.65, Down -6.53 - DWinneX

Calidi (CLDI) Advances Cancer Treatment with IL15 Superagonist a - GuruFocus

Calidi Biotherapeutics Announces IL15 Superagonist as First - GlobeNewswire

Revolutionary Cancer Treatment Platform Shows Complete Tumor Elimination: First Systemic Delivery Success - Stock Titan

Calidi Biotherapeutics (CLDI) Awards Stock Option to New CEO Eri - GuruFocus

Calidi Biotherapeutics Reports Inducement Grant Under NYSE American LLC Company Guide Section 711 - The Manila Times

Calidi Bio's Strategic Move: New CEO Secures 726K Share Options with 4-Year Performance Lock - Stock Titan

Calidi Biotherapeutics appoints new CEO By Investing.com - Investing.com South Africa

Zealand names former Lilly exec Singh as CSO - BioCentury

Calidi Biotherapeutics appoints new CEO - Investing.com

Calidi (CLDI) Appoints New CEO as Eric Poma Assumes Leadership | - GuruFocus

Calidi Biotherapeutics Appoints New CEO Eric Poma - TipRanks

Calidi Biotherapeutics Announces Chief Executive Officer Transition And Appointment Of Eric Poma, Ph.D. As CEO And Director - TradingView

Calidi Biotherapeutics Announces Chief Executive Officer - GlobeNewswire

New Calidi Bio CEO Brings $400M Funding Success Record: Strategic Shift for Cancer Treatment Pioneer - Stock Titan

Calidi Biotherapeutics Announces Appointment of Guy Travis Clifton, MD as Chief Medical Officer, Consultant and Advisor - The Globe and Mail

Join Calidi Biotherapeutics' Exclusive Live Investor Webinar and Q&A Session on April 24 - The Manila Times

Join Calidi Biotherapeutics’ Exclusive Live Investor Webinar and Q&A Session on April 24 - GlobeNewswire

Cancer Breakthrough Alert: Top Oncologist Reveals New FDA-Cleared Stem Cell Therapy Development - Stock Titan

Calidi Biotherapeutics Announces FDA Clearance of IND Application for CLD-201 in Solid Tumors - The Manila Times

FDA Green Lights Revolutionary Cancer Treatment: Stem Cells Combined With Virus to Fight Multiple Tumors - Stock Titan

Calidi Biotherapeutics Announces Appointment of Guy Travis - GlobeNewswire

Cancer Drug Developer Calidi Bio Strengthens Leadership: Renowned Oncologist Takes CMO Role - Stock Titan

Calidi Biotherapeutics Appoints New Chief Medical Officer - TipRanks

CLDI stock touches 52-week low at $0.42 amid market challenges By Investing.com - Investing.com South Africa

CLDI stock touches 52-week low at $0.42 amid market challenges - Investing.com India

Press Release Distribution & PR Platform - ACCESS Newswire

ASP Isotopes and Calidi Biotherapeutics Interviews to Air on the RedChip Small Stocks, Big Money(TM) Show on Bloomberg TV - ACCESS Newswire

HighTower Advisors LLC Makes New Investment in Calidi Biotherapeutics, Inc. (NYSE:CLDI) - Defense World

Calidi Biotherapeutics Reports Fourth Quarter and Full-Year 2024 Financial Results and Recent Operational Highlights - The Manila Times

Calidi Biotherapeutics Announces Closing of $3.9 Million Registered Direct Offering and Concurrent Private Placement - GlobeNewswire

CLDI stock plunges to 52-week low, hitting $0.57 amid market challenges By Investing.com - Investing.com South Africa

Calidi Bio Raises Fresh $3.9M Capital to Advance Clinical Programs - Stock Titan

Finanzdaten der Calidi Biotherapeutics Inc-Aktie (CLDI)

Umsatz

Nettogewinn

Free Cashflow

ENV

Ähnlich wie CLDI